已传文件：photo/1773121782.png
Article Information
Hepatocellular carcinoma is a typical "cold tumor", and the effect of immunotherapy is limited. Moreover, abnormal metabolism of tumor cells and the immunosuppressive microenvironment (TME) further reduce the anti-tumor efficacy of ferroptosis and cuproptosis. Recently, a research team from the Affiliated Hospital of Guilin Medical University and Zhongda Hospital of Southeast University published a significant study in Advanced Science, designing a new type of bimetallic organic framework nanomaterial PEG@AuCZ@CC. By integrating ferroptosis-cuproptosis co-induction, metabolic reprogramming and immune microenvironment remodeling, this research achieved efficient treatment of hepatocellular carcinoma, providing a new paradigm for immunotherapy of cold tumors!
Key Points Analysis
Research Background: Two major challenges in hepatocellular carcinoma immunotherapy
The core reasons why hepatocellular carcinoma is insensitive to immunotherapy are as follows:
1. Deep-rooted immunosuppressive microenvironment: Tumor-associated macrophages (TAMs) polarize towards the pro-tumor M2 type, CD4+/CD8+ T cells are impaired due to glucose deficiency and high lactate environment, while regulatory T cells (Treg) can stably exert immunosuppressive effects in such harsh conditions;
2. Limited efficacy of single cell death mode: Traditional apoptosis induction is prone to drug resistance, while ferroptosis and cuproptosis have potential, but the antioxidant system and metabolic characteristics of tumor cells will weaken their effects, and the immunogenic cell death (ICD) effect is insufficient, making it difficult to effectively activate systemic anti-tumor immunity.
To address these issues, the research team innovatively designed the PEG@AuCZ@CC nanoplatform, integrating the catalytic properties of metal nanoenzymes, dual cell death induction, metabolic reprogramming and immune microenvironment regulation to achieve multimodal synergistic anti-tumor.
Core Design: Construction and Characteristics of PEG@AuCZ@CC Nanomaterials
1. Material Synthesis and Structural Characterization
The research used ZIF-8 as the base, through one-pot method to co-dopant copper ions, load oxidized carotenene (CO) and α-cyano-4-hydroxy-cinnamic acid (CHCA), and perform in situ reduction of chloroauric acid to obtain Au nanoparticles. Finally, the surface was modified with DSPE-PEG2000-GA to obtain PEG@AuCZ@CC nanoparticles (Figure 1A).
· Morphologically, PEG@AuCZ@CC is spherical, with good dispersion, and Au nanoparticles (2-3 nm) are uniformly distributed on the surface, forming a transparent coating after PEG modification (Figure 1B-D);
· Elemental analysis confirmed the successful loading of Zn, Cu, Au and drug components. XRD results indicated that the synthesis and modification process did not damage the crystal structure of ZIF-8, and PEG modification improved the structural stability;
· The particle size is approximately 311.70 nm, with a zeta potential of -8.34 mV. The particle size and zeta potential did not change significantly in the serum environment within 5 days, demonstrating excellent physiological stability;
· Drug loading rate: CO is 4.7%, and CHCA is 6.6%, and it has pH-responsive drug release characteristics. It releases rapidly in the acidic tumor microenvironment (pH 5.4/6.4) and slowly in the neutral physiological environment, achieving tumor-targeted drug delivery.
2. Key Enzymatic Activity
PEG@AuCZ@CC combines glucose oxidase (GOx)-like activity and glutathione (GSH) depletion ability, laying the foundation for subsequent cell death induction:
· The Au nanoparticles simulate GOx, catalyzing glucose oxidation to generate H₂O₂ and glucose acid, achieving glucose depletion and H₂O₂ enrichment within the tumor;
· Copper ions can be reduced by GSH to Cu⁺, efficiently depleting GSH within tumor cells and disrupting their antioxidant system, enhancing oxidative stress.
DOI: 10.1002/advs.202512764
